Haemophilus influenzae type b capsular polysaccharide conjugated to Neisseria meningitidis outer membrane protein complex and Hepatitis B surface antigen (PRP-OMPC/HBsAg)

This target refers to the combination of antigens used in pediatric vaccines to provide protection against Haemophilus influenzae type b (Hib) and the Hepatitis B virus (HBV) (Source: CDC, 2023). The PRP-OMPC component consists of the Hib capsular polysaccharide, polyribosylribitol phosphate (PRP), covalently linked to the outer membrane protein complex (OMPC) of Neisseria meningitidis (Source: PubChem, CID 139595264). This conjugation is critical for converting the polysaccharide into a T-cell dependent antigen, ensuring an effective immune response and long-term memory in young infants whose immune systems do not respond well to pure polysaccharides (Source: PubMed, PMID 12145534). The HBsAg component is a recombinant surface antigen of the Hepatitis B virus that induces the production of neutralizing antibodies (Source: WHO, 2020). Together, these antigens stimulate the immune system to develop protective antibody titers, significantly reducing the incidence of invasive Hib diseases like meningitis and chronic liver disease associated with HBV (Source: FDA, Comvax Package Insert). This specific combination was the basis for the Comvax vaccine, designed to simplify the infant immunization schedule.

Other names

Hib-HepB vaccineComvax componentsPRP-OMPC-HBsAgHaemophilus b Conjugate Vaccine and Hepatitis B Vaccine (Recombinant)Polyribosylribitol phosphate-Outer Membrane Protein Complex and Hepatitis B surface Antigen

The mechanism involves the induction of active immunity through the presentation of specific antigens to the immune system. The PRP-OMPC component utilizes a carrier protein (OMPC) to convert the T-cell independent PRP polysaccharide into a T-cell dependent antigen, allowing for MHC II presentation and the stimulation of T-helper cells, which is essential for an effective response in infants (Source: PubMed, PMID 10431971). The HBsAg component is recognized by B-cells, leading to the production of neutralizing anti-HBs antibodies that prevent the Hepatitis B virus from infecting hepatocytes (Source: StatPearls, 2023).